These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 25636162)

  • 1. Epidermal growth factor receptor-directed monoclonal antibodies in nonsmall cell lung cancer: an update.
    Pirker R
    Curr Opin Oncol; 2015 Mar; 27(2):87-93. PubMed ID: 25636162
    [TBL] [Abstract][Full Text] [Related]  

  • 2. EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study.
    Pirker R; Pereira JR; von Pawel J; Krzakowski M; Ramlau R; Park K; de Marinis F; Eberhardt WE; Paz-Ares L; Störkel S; Schumacher KM; von Heydebreck A; Celik I; O'Byrne KJ
    Lancet Oncol; 2012 Jan; 13(1):33-42. PubMed ID: 22056021
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Monoclonal antibodies against EGFR in non-small cell lung cancer.
    Pirker R; Filipits M
    Crit Rev Oncol Hematol; 2011 Oct; 80(1):1-9. PubMed ID: 21109448
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical relevance of monoclonal antibodies in non small cell lung cancer.
    Filipits M
    J BUON; 2009 Sep; 14 Suppl 1():S147-52. PubMed ID: 19785057
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Necitumumab in the treatment of advanced non-small cell lung cancer: translation from preclinical to clinical development.
    Dienstmann R; Felip E
    Expert Opin Biol Ther; 2011 Sep; 11(9):1223-31. PubMed ID: 21679088
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Correlation of EGFR-expression with safety and efficacy outcomes in SQUIRE: a randomized, multicenter, open-label, phase III study of gemcitabine-cisplatin plus necitumumab versus gemcitabine-cisplatin alone in the first-line treatment of patients with stage IV squamous non-small-cell lung cancer.
    Paz-Ares L; Socinski MA; Shahidi J; Hozak RR; Soldatenkova V; Kurek R; Varella-Garcia M; Thatcher N; Hirsch FR
    Ann Oncol; 2016 Aug; 27(8):1573-9. PubMed ID: 27207107
    [TBL] [Abstract][Full Text] [Related]  

  • 7. First-line treatment for advanced non-small-cell lung cancer.
    Laskin JJ; Sandler AB
    Oncology (Williston Park); 2005 Nov; 19(13):1671-6; discussion 1678-80. PubMed ID: 16425521
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Necitumumab for non-small cell lung cancer.
    Greillier L; Tomasini P; Barlesi F
    Expert Opin Biol Ther; 2015; 15(8):1231-9. PubMed ID: 26051700
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Necitumumab: a new option for first-line treatment of squamous cell lung cancer.
    Jiménez Aguilar E; Zugazagoitia Fraile J; Paz-Ares Rodríguez L
    Expert Opin Drug Metab Toxicol; 2018 Aug; 14(8):765-772. PubMed ID: 30025476
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Necitumumab plus Gemcitabine and Cisplatin as First-Line Therapy in Patients with Stage IV EGFR- Expressing Squamous Non-Small-Cell Lung Cancer: German Subgroup Data from an Open-Label, Randomized Controlled Phase 3 Study (SQUIRE).
    Reck M; Thomas M; Kropf-Sanchen C; Mezger J; Socinski MA; Depenbrock H; Soldatenkova V; Brown J; Krause T; Thatcher N
    Oncol Res Treat; 2016; 39(9):539-47. PubMed ID: 27614872
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is there still room for large registrative trials in unselected cancer patients? The case of anti-epidermal growth factor receptor antibodies in advanced non-small-cell lung cancer.
    Di Maio M
    Expert Opin Biol Ther; 2011 Sep; 11(9):1131-3. PubMed ID: 21806477
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relationship between EGFR expression, EGFR mutation status, and the efficacy of chemotherapy plus cetuximab in FLEX study patients with advanced non-small-cell lung cancer.
    Douillard JY; Pirker R; O'Byrne KJ; Kerr KM; Störkel S; von Heydebreck A; Grote HJ; Celik I; Shepherd FA
    J Thorac Oncol; 2014 May; 9(5):717-24. PubMed ID: 24662454
    [TBL] [Abstract][Full Text] [Related]  

  • 13. First-cycle rash and survival in patients with advanced non-small-cell lung cancer receiving cetuximab in combination with first-line chemotherapy: a subgroup analysis of data from the FLEX phase 3 study.
    Gatzemeier U; von Pawel J; Vynnychenko I; Zatloukal P; de Marinis F; Eberhardt WE; Paz-Ares L; Schumacher KM; Goddemeier T; O'Byrne KJ; Pirker R
    Lancet Oncol; 2011 Jan; 12(1):30-7. PubMed ID: 21169060
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Implications of key trials in advanced nonsmall cell lung cancer.
    Bonomi PD
    Cancer; 2010 Mar; 116(5):1155-64. PubMed ID: 20087963
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Necitumumab for the treatment of advanced non-small-cell lung cancer.
    Díaz-Serrano A; Sánchez-Torre A; Paz-Ares L
    Future Oncol; 2019 Mar; 15(7):705-716. PubMed ID: 30501503
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epidermal growth factor receptor tyrosine kinase inhibitors in early-stage nonsmall cell lung cancer.
    Spaans JN; Goss GD
    Curr Opin Oncol; 2015 Mar; 27(2):102-7. PubMed ID: 25611026
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical experience with the HER1/EGFR tyrosine kinase inhibitor erlotinib.
    Sandler A
    Oncology (Williston Park); 2003 Nov; 17(11 Suppl 12):17-22. PubMed ID: 14682119
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of advanced non-small-cell lung cancer in the elderly.
    Gridelli C; Maione P; Rossi A; Ferrara ML; Castaldo V; Palazzolo G; Mazzeo N
    Lung Cancer; 2009 Dec; 66(3):282-6. PubMed ID: 19879012
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study.
    Seto T; Kato T; Nishio M; Goto K; Atagi S; Hosomi Y; Yamamoto N; Hida T; Maemondo M; Nakagawa K; Nagase S; Okamoto I; Yamanaka T; Tajima K; Harada R; Fukuoka M; Yamamoto N
    Lancet Oncol; 2014 Oct; 15(11):1236-44. PubMed ID: 25175099
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and Safety of Necitumumab Continuation Therapy in the Phase III SQUIRE Study of Patients With Stage IV Squamous Non-Small-Cell Lung Cancer.
    Ciuleanu T; Socinski MA; Obasaju C; Luft AV; Szczesna A; Szafrański W; Ramlau R; Bálint B; Molinier O; Depenbrock H; Nanda S; Paz-Ares L; Thatcher N
    Clin Lung Cancer; 2018 Mar; 19(2):130-138.e2. PubMed ID: 29158123
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.